NCT05046899 is a NA clinical trial of BIOpH+ Psoriasis Medical Bath in Plaque Psoriasis, sponsored by Biocool AB.

Who is sponsoring NCT05046899?

NCT05046899 is sponsored by Biocool AB.

What drugs are being tested in NCT05046899?

Interventions in NCT05046899: BIOpH+ Psoriasis Medical Bath, Cetaphil Moisturizing Lotion.

What condition does NCT05046899 study?

NCT05046899 studies Plaque Psoriasis.

Is NCT05046899 still recruiting?

NCT05046899 is currently completed. Last updated 6 October 2022.

Last reviewed 2022-10-06 · How we verify

NCT05046899

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.

Completed NA Last updated 6 October 2022

What this trial tests

NA trial testing BIOpH+ Psoriasis Medical Bath in Plaque Psoriasis in 25 participants. Completed in 13 June 2022.

Timeline

14 September 2021

Primary endpoint
31 May 2022

13 June 2022

Quick facts

Lead sponsor	Biocool AB
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	14 September 2021
Primary completion	31 May 2022
Estimated completion	13 June 2022
Sites	1 location across Sweden

Drugs / interventions tested

BIOpH+ Psoriasis Medical Bath
Cetaphil Moisturizing Lotion

Conditions studied

Plaque Psoriasis — all drugs for Plaque Psoriasis →

Sponsor

Biocool AB

Who can join

18 and older, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this investigation is to assess performance and safety of BIOpH+ Psoriasis Medical Bath in comparison to a comparative device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Plaque Psoriasis

Currently open trials in the same condition.

NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting

Other Biocool AB trials

Trials by the same sponsor.

NCT04265521 — Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05046899 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biocool AB
Last refreshed: 6 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05046899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing